Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer

Breast Cancer Research and Treatment

Volumn 116, Issue 3, 2009, Pages 595-602

  Dignam, James J ^a,b   Dukic, Vanja ^a   Anderson, Stewart J ^b,c   Mamounas, Eleftherios P ^b,d   Wickerham, D Lawrence ^b,e   Wolmark, Norman ^b,e  

^a UNIVERSITY OF CHICAGO   (United States)

^b NSABP Foundation Inc   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d Altman Cancer Center   (United States)

^e ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

Estrogen receptor; Hazard Prognosis; Lymph node negative; Systemic adjuvant therapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PLACEBO; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RISK ASSESSMENT; RISK REDUCTION; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CANCER INVASION; CANCER STAGING; COHORT ANALYSIS; LYMPH NODE; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ESTROGEN; TAMOXIFEN; TREATMENT OUTCOME;

EID: 70349582555     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0200-5     Document Type: Article

References (45)

1. National Institutes of Health Consensus Development Panel (2001) National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst Monogr 30:5-15
2. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival. Lancet 365:1687-1717
3. Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826
4. Paik S, Tang G, Shak S et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734
5. Robbins GF, Berg J (1977) Curability of patients with invasive breast carcinoma based on a 30-year study. World J Surg 1: 284-286
6. Karrison T, Ferguson D, Meier P (1999) Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst 91:80-85
7. Saphner T, Tormey D, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738-2746
8. Hilsenbeck SG, Ravdin PM, de Moor CA et al (1998) Timedependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 52:227-237
9. Hess K, Pusztai L, Buzdar A et al (2003) Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 78:105-118
10. Anderson WF, Chen RE, Jatoi I et al (2006) Effect of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer. Breast Cancer Res Treat 100:121-126
11. Fisher B, Jeong J-H, Anderson S et al (2004) Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. J Natl Cancer Inst 96:1823-1831
12. Fisher B, Jeong J-H, Bryant J et al (2004) Treatment of lymph node-negative, estrogen receptor-positive breast cancer: longterm findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. Lancet 364:858-868
13. Fisher B, Redmond C, Dimitrov NV et al (1989) A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 320: 473-478
14. Fisher B, Dignam J, Mamounas EP et al (1996) Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol 14:1982-1992
15. Fisher B, Anderson S, Tan-Chiu E et al (2001) Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 19:931-942
16. Fisher B, Costantino J, Redmond C et al (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor positive tumors. N Engl J Med 320:479-484
17. Fisher B, Dignam J, Bryant J et al (1996) Five versus more than five years of tamoxifen for lymph node-negative breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 88:1529-1542
18. Fisher B, Dignam JJ, Wolmark N et al (1997) Tamoxifen and chemotherapy for lymph node-negative, estrogen-receptor positive breast cancer. J Natl Cancer Inst 89:1673-1682
19. Cox DR (1972) Regression models and life tables. J R Stat Soc B 34:187-220
20. Prentice RL, Kalbfleisch JD, Peterson AV et al (1978) The analysis of failure times in the presence of competing risks. Biometrics 34:541-554
21. Kalbfleisch J, Prentice R (1980) The statistical analysis of failure time data. Wiley, New York
22. Sargent D (1997) A flexible approach to time-varying coefficients in the Cox regression setting. Lifetime Data Anal 3:13-25
23. Gray RJ (1992) Flexible methods for analyzing survival data using splines, with applications to breast cancer prognosis. J Am Stat Assoc 87:942-951
24. Hess KR (1994) Assessing time-by-covariate interactions in proportional hazards regression models using cubic spline functions. Stat Med 13:1045-1062
25. Grambsch PM, Therneau TM, Fleming TR (1995) Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. Biometrics 51:1469-1482
26. Müller HG, Wang JL (1994) Hazard rates estimation under random censoring with varying kernels and bandwidths. Biometrics 50:61-76
27. Hess KR, Serachitopol DM, Brown BW (1999) Hazard function estimators: a simulation study. Stat Med 18:3075-3088
28. Berry DA, Cirrincione C, Henderson IC et al (2006) Estrogenreceptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658-1667
29. Cardoso F, Van't Veer L, Rutgers E et al (2008) Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 26:729-735
30. Bryant J, Fisher B, Gündüz N et al (1998) S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 51:239-253
31. Goss PE, Ingle JN, Martino S et al (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17. J Natl Cancer Inst 97:1262-1271
32. Goss PE, Ingle JN, Pater JL et al (2008) Late extended adjuvant treatment with letrozole improves outcome in women with earlystage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 26:1948-1955
33. Mamounas EP, Jeong JH, Wickerham DL et al (2008) Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol 26:1965-1971
34. Lin NU, Winer EP (2008) Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol 26:798-805
35. Aalen O, Gjessing H (2001) Understanding the shape of the hazard rate: a process point of view. Stat Sci 16:1-22
36. Singpurwulla N (2006) The hazard potential: introduction and overview. J Am Stat Assoc 101:1705-1717
37. Lawless J (1982) Statistical models and methods for lifetime data. Wiley, New York
38. Berry D (2005) Breast cancer heterogeneity may explain peaks in recurrence. Int J Surg 3:287
39. Dignam JJ, Dukic V (2008) Comment on: Yin W Di G, Zhou L et al. Time-varying patterns of recurrence risk for Chinese breast cancer patients. Breast Cancer Res Treat Jun 21 (Epub ahead of print)
40. Demicheli R, Abbattista A, Miceli R et al (1996) Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res Treat 41:177-185
41. Demicheli R, Valagussa P, Bonadonna G (2001) Does surgery modify growth kinetics of breast cancer micrometastases? Br J Cancer 85:490-492
42. Baum M, Cuzick J, Howell A et al (2005) An exploration of relapse data by hazard rate as a means of developing biological insights into the natural history and treatment of breast cancer. J Clin Oncol. 2005 ASCO annual meeting proceedings, vol 23, No. 16S (June 1 Supplement), p 612
43. Rastogi P, Anderson SJ, Bear HD et al (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26:778-785
44. Jeong JH, Jung SH, Wieand S (2003) A parametric model for long-term follow-up data from phase III breast cancer clinical trials. Stat Med 22:339-352
45. Dukic V, Dignam J (2007) Bayesian hierarchical multiresolution model for the study of time-dependent patterns of failure in early stage breast cancer. Bayesian Anal 2:591-610